Generating power with blood sugar

Zurich, 29 March 2023:A fuel cell under the skin that converts blood sugar from the body into electrical energy sounds like science fiction. Yet it works perfectly, as an ETH Zurich research team led by Martin Fussenegger, Professor of Biotechnology and Bioengineering, has shown.

In type 1 diabetes, the body does not produce insulin. This means that patients have to obtain the hormone externally to regulate their blood sugar levels. Nowadays, this is mostly done via insulin pumps that are attached directly to the body. These devices, as well as other medical applications such as pacemakers, require a reliable energy supply, which at present is met primarily by power from either single-use or rechargeable batteries.

Now, a team of researchers led by Martin Fussenegger from the Department of Biosystems Science and Engineering at ETH Zurich in Basel have put a seemingly futuristic idea into practice. They have developed an implantable fuel cell that uses excess blood sugar (glucose) from tissue to generate electrical energy. The researchers have combined the fuel cell with artificial beta cells developed by their group several years ago. These produce insulin at the touch of a button and effectively lower blood glucose levels much like their natural role models in the pancreas.

“Many people, especially in the Western industrialized nations, consume more carbohydrates than they need in everyday life,” Fussenegger explains. This, he adds, leads to obesity, diabetes, and cardiovascular disease. “This gave us the idea of using this excess metabolic energy to produce electricity to power biomedical devices,” he says.

Fuel cell in tea bag format

At the heart of the fuel cell is an anode (electrode) made of copper-based nanoparticles, which Fussenegger’s team created specifically for this application. It consists of copper-based nanoparticles and splits glucose into gluconic acid and a proton to generate electricity, which sets an electric circuit in motion.

Wrapped in a nonwoven fabric and coated with alginate, an algae product approved for medical use, the fuel cell resembles a small tea bag that can be implanted under the skin. The alginate soaks up body fluid and allows glucose to pass from the tissue into the fuel cell within.

A diabetes network with its own power supply
In a second step, the researchers coupled the fuel cell with a capsule containing artificial beta cells. These can be stimulated to produce and secrete insulin using electric current or blue LED light. Fussenegger and his colleagues already tested such designer cells some time ago. (see ETH News, 8 December 2016)

The system combines sustained power generation and controlled insulin delivery. As soon as the fuelcell registers excess glucose, it starts to generate power. This electrical energy is then used to stimu-late the cells to produce and release insulin into the blood. As a result, blood sugar dips to a normal level. Once it falls below a certain threshold value, the production of electricity and insulin stops.

The electrical energy provided by the fuel cell is sufficient not only to stimulate the designer cells but also to enable the implanted system to communicate with external devices such as a smartphone. This allows potential users to adjust the system via a corresponding app. A doctor could also access it remotely and make adjustments. “The new system autonomously regulates insulin and blood glucose levels and could be used to treat diabetes in the future,” Fussenegger says.

A long, uncertain road to market maturity
The existing system is only a prototype. Although the researchers have successfully tested it in mice, they are unable to develop it into a marketable product. “Bringing such a device to market is far beyond our financial and human resources,” Fussenegger says. This would call for an industry partner with the appropriate resources and know-how.

References

Maity, D., Ray, P.G., Buchmann, P., Mansouri, M. and Fussenegger, M. (2023), Blood-Glucose-Pow-ered Metabolic Fuel Cell for Self-Sufficient Bioelectronics. Adv. Mater. Accepted Author Manuscript:

2300890. https://doi.org/10.1002/adma.202300890

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Shriram General Insurance Company welcomes IRDAI’s decision to remove cap on commission payments
Next post 5 fastest growing B2B Ed-Tech companies making learning easier with Gamification